Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.
Eur J Clin Invest. 2014;44(3):231-9. doi: 10.1111/eci.12222. Epub 2013 Dec 27.
Previous studies demonstrated the prognostic importance of concomitant polyvascular disease in patients with coronary artery disease (CAD). However, the significance of the number of diseased vascular territories and subclinical disease is unknown.
The number of diseased vascular territories was evaluated in 2299 percutaneous coronary intervention (PCI) patients. Vascular disease was defined by documented atherosclerotic disease, either diagnosed in the medical history (clinical) or at the standardized cardiovascular screening (subclinical). The following territories were evaluated: cerebrovascular disease, peripheral arterial disease, abdominal aortic aneurysm and vascular renal disease. The outcome measures were all-cause mortality, cardiovascular mortality and a composite cardiovascular endpoint (myocardial infarction, stroke, cardiovascular mortality). Patients with monovascular disease (CAD) served as the reference category. Hazard ratios (HRs) were adjusted for baseline characteristics.
Mean follow-up was 7.3 years. The HRs (95% confidence interval) for patients with two diseased territories compared to monovascular disease were for all-cause mortality 1.60 (1.14-2.25), cardiovascular mortality 2.13 (1.29-3.50) and the combined cardiovascular endpoint 1.66 (1.20-2.31). Moreover, the HRs (95% confidence intervals) for patients with more than two diseased territories compared to monovascular disease were for all-cause mortality 3.81 (2.45-5.92), cardiovascular mortality 4.40 (2.32-8.35) and the combined cardiovascular endpoint 2.75 (1.69-4.47). The HRs of patients with subclinical disease were comparable to the HRs of patients with clinical disease.
In patients undergoing PCI, the presence of subclinical and clinical polyvascular disease is associated with an increased long-term mortality and morbidity. Moreover, the outcome is highly influenced by the number of diseased territories.
先前的研究表明,在患有冠状动脉疾病(CAD)的患者中,同时存在多血管疾病具有预后意义。然而,尚不清楚患病血管区域的数量和亚临床疾病的意义。
在 2299 名经皮冠状动脉介入治疗(PCI)患者中评估了患病血管区域的数量。血管疾病通过病史中记录的动脉粥样硬化疾病(临床)或标准化心血管筛查(亚临床)来定义。评估了以下区域:脑血管疾病、外周动脉疾病、腹主动脉瘤和血管性肾病。主要终点是全因死亡率、心血管死亡率和复合心血管终点(心肌梗死、中风、心血管死亡率)。单血管疾病(CAD)患者作为参考类别。风险比(HR)根据基线特征进行调整。
平均随访时间为 7.3 年。与单血管疾病相比,患有两个患病区域的患者的全因死亡率、心血管死亡率和复合心血管终点的 HR(95%置信区间)分别为 1.60(1.14-2.25)、2.13(1.29-3.50)和 1.66(1.20-2.31)。此外,与单血管疾病相比,患有两个以上患病区域的患者的全因死亡率、心血管死亡率和复合心血管终点的 HR(95%置信区间)分别为 3.81(2.45-5.92)、4.40(2.32-8.35)和 2.75(1.69-4.47)。亚临床疾病患者的 HR 与临床疾病患者的 HR 相当。
在接受 PCI 的患者中,亚临床和临床多血管疾病的存在与长期死亡率和发病率增加相关。此外,疾病区域的数量对结果有很大影响。